GDC0152 is primarily used in research settings to study its potential as an anticancer agent. It functions as an inhibitor of the IAP (inhibitor of apoptosis proteins) family, which plays a critical role in regulating cell death. By blocking these proteins, GDC0152 promotes apoptosis in cancer cells, making it a promising candidate for cancer therapy. It is often employed in preclinical studies to evaluate its efficacy in inducing tumor cell death and its potential to enhance the effects of other anticancer treatments. Researchers also explore its application in overcoming drug resistance in various cancers, particularly those with upregulated IAP expression. Additionally, GDC0152 is used in biochemical assays to better understand the mechanisms of apoptosis and to identify potential biomarkers for cancer treatment response.